Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 8,722 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part A Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal

NCT01872910
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, LY3023703, Celecoxib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

NCT03441984
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 20, 2026, 10:59 AM EDT
Completed No phase listed Observational Results available

Associated Joint Pain With Controlled Ankle Movement (CAM) Walker Boot Wear

NCT03312933
View directory record Official record
Conditions
Pain, Ankle Injuries
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 20, 2026, 10:59 AM EDT
Recruiting Not applicable Interventional

How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes

NCT06817252
View directory record Official record
Conditions
Prediabetes, Lipid Profile, Hypertension, Glycemic Control, Arterial Stiffness, Blood Pressure, Inflammation Biomarkers, Dietary Quality, Body Composition Measurement, Waist Circumference, Anthropometrics: Height and Weight
Interventions
Mediterranean Diet Nutrition Education, Mediterranean Diet Nutrition Education with Baked White Potato
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors

NCT01999738
View directory record Official record
Conditions
Solid Tumors, Non Small Cell Lung Carcinoma
Interventions
EC1456 and EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 20, 2026, 10:59 AM EDT
Recruiting Phase 4 Interventional

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

NCT07136415
View directory record Official record
Conditions
Menopausal Women, Insomnia
Interventions
Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant
Behavioral · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Boston, Massachusetts • Novi, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

NCT07867340
View directory record Official record
Conditions
C-Reactive Protein
Interventions
LY5625573, Midazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Alamitos, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Enrolling by invitation Not applicable Interventional

Lock and Protect: Reducing Adolescent Access to Lethal Means of Suicide

NCT07111052
View directory record Official record
Conditions
Suicide, Suicide Attempt, Adolescent Suicidality, Suicide Ideation
Interventions
Lock and Protect is a self-administered, web-based decision aid for caregivers of adolescents at risk for suicide.
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 20, 2026, 10:59 AM EDT
Recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Chandler, Arizona • Duarte, California • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

NCT02853435
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

NCT02055703
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, itraconazole, rifampin, digoxin, donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

NCT03377361
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
Interventions
Nivolumab, Trametinib, Ipilimumab, Regorafenib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 20, 2026, 10:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

NCT02797470
View directory record Official record
Conditions
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Melphalan, Peripheral Blood Stem Cell Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
4
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function

NCT02460783
View directory record Official record
Conditions
Alzheimer's Disease, Obesity, Diabetes Mellitus
Interventions
Boost (R) 5-2 diet, Healthy Living Diet
Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 20, 2026, 10:59 AM EDT
Terminated Phase 1 Interventional Results available

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

NCT06039384
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
INCB099280, adagrasib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

NCT03912233
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 20, 2026, 10:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions
IDE-161, Pembrolizumab
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

NCT07404306
View directory record Official record
Conditions
General Anesthesia
Interventions
HSK3486, propofol, Placebo
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Results available

Project OOPEN: Opioid Overdose Prevention, Education and Intervention

NCT01788306
View directory record Official record
Conditions
Opioid Overdose
Interventions
OOPEN+BBCC
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of LY2811376 Single Doses in Healthy Subjects

NCT00838084
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2811376, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

NCT04452214
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions
CAN04, Pembrolizumab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Cantargia AB
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Lake Mary, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

NCT03144804
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Lamivudine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 20, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

NCT03341806
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
Avelumab, MRI-guided LITT therapy
Drug · Combination Product
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 20, 2026, 10:59 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

NCT03833206
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 10:59 AM EDT